Teva Pharmaceutical Industries Long-Term Investments 2010-2024 | TEVA

Teva Pharmaceutical Industries long-term investments from 2010 to 2024. Long-term investments can be defined as the aggregate value of debt and or equity investments with maturities or benefits lasting more than one year.
  • Teva Pharmaceutical Industries long-term investments for the quarter ending September 30, 2024 were $M, a NAN% increase year-over-year.
  • Teva Pharmaceutical Industries long-term investments for 2023 were $0B, a NAN% decline from 2022.
  • Teva Pharmaceutical Industries long-term investments for 2022 were $0B, a NAN% decline from 2021.
  • Teva Pharmaceutical Industries long-term investments for 2021 were $0B, a NAN% decline from 2020.
Teva Pharmaceutical Industries Annual Long-Term Investments
(Millions of US $)
2023 $
2022 $
2021 $
2020 $
2019 $
2018 $
2017 $
2016 $
2015 $
2014 $
2013 $
2012 $
2011 $
2010 $632
2009 $534
Teva Pharmaceutical Industries Quarterly Long-Term Investments
(Millions of US $)
2024-09-30
2024-06-30
2024-03-31
2023-12-31
2023-09-30
2023-06-30
2023-03-31
2022-12-31
2022-09-30
2022-06-30
2022-03-31
2021-12-31
2021-09-30
2021-06-30
2021-03-31
2020-12-31
2020-09-30
2020-06-30
2020-03-31
2019-12-31
2019-09-30
2019-06-30
2019-03-31
2018-12-31
2018-09-30
2018-06-30
2018-03-31
2017-12-31
2017-09-30
2017-06-30
2017-03-31
2016-12-31
2016-09-30
2016-06-30
2016-03-31
2015-12-31
2015-09-30
2015-06-30
2015-03-31
2014-12-31
2014-09-30
2014-06-30
2014-03-31
2013-12-31
2013-09-30
2013-06-30
2013-03-31
2012-12-31
2012-09-30 $1,208
2012-06-30 $1,115
2012-03-31 $1,044
2011-12-31
2011-09-30 $589
2011-06-30 $650
2011-03-31 $671
2010-12-31 $632
2010-09-30 $680
2010-06-30 $628
2010-03-31 $665
2009-12-31 $534
2009-09-30 $484
2009-06-30 $459
2009-03-31 $406
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $19.384B $15.846B
Teva Pharmaceutical Industries Limited is a global pharmaceutical company that develops, manufactures, and markets both branded and generic drugs, as well as active pharmaceutical ingredients in North America, Europe, Latin America, India, and Israel. Teva's generic product portfolio includes tablets, capsules, liquids, ointments, creams, liquids, injectables, and inhalants. The company's branded products include Copaxone, Austedo, respiratory products like ProAir and Qvar and Ajovy. Teva operates through three segments, North America, Europe and International Markets, each of which includes generics, specialty and over-the-counter products. Teva acquired Allergan's generics business Actavis Generics. The company also acquired Allergan's Anda Inc. Teva acquired Auspex Pharmaceuticals and Barr. Teva has strengthened its position in Europe through its acquisition of Germany's second largest generics producer, ratiopharm.
Stock Name Country Market Cap PE Ratio
Dr Reddy's Laboratories (RDY) India $12.329B 23.59
BridgeBio Pharma (BBIO) United States $4.629B 0.00
Bausch Health Cos (BHC) Canada $3.358B 2.43
Amphastar Pharmaceuticals (AMPH) United States $2.294B 13.79
Supernus Pharmaceuticals (SUPN) United States $2.089B 28.44
Taysha Gene Therapies (TSHA) United States $0.490B 79.67
Personalis (PSNL) United States $0.278B 0.00
Assembly Biosciences (ASMB) United States $0.105B 0.00
Sol-Gel Technologies (SLGL) Israel $0.016B 0.00
Evoke Pharma (EVOK) United States $0.004B 0.00
Teligent (TLGT) United States $0.000B 0.00